Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories has secured an exclusive license from Ingenus Pharmaceuticals to commercialize Cyclophosphamide Injection RTD in the U.S., with an agreement to pay Ingenus a 50% profit share. The deal is significant as the product has reported sales of $51.8 million over the past year. This strategic move is expected to bolster Dr. Reddy’s presence in the U.S. pharmaceutical market.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
